Health and correctional staff acceptability of depot buprenorphine in NSW prisons

Original research
by
Little, S.C. et al

Release Date

2023

Geography

Australia

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

Yes

Peer Reviewed

Yes

Objective

A clinical trial of a new OAT, depot buprenorphine provided the opportunity to obtain health and correctional staff perspectives regarding this treatment prior to widespread roll-out.

Findings/Key points

The introduction of depot buprenorphine into correctional settings was considered to have the potential to increase safety for patients, improve staff / patient relations and advance patient health outcomes via expanded treatment coverage and efficiencies gained through enhanced health service delivery. Support was almost universal from both correctional and health staff participating in this study. These findings build on emerging research regarding the positive impact of more flexible OAT programs and could be used to engage support for the implementation of depot buprenorphine from staff in other secure settings.

Design/methods

Sixteen focus groups with 52 participants were conducted, including 44 health staff (nurses, nurse practitioners, doctors, and operational staff) and eight correctional staff.

Keywords

Substitution/OAT
Legal system/law enforcement
About prescribers